GlassScriptPhysician profile
Emma Middleton
NPI 1932679875
$5,855.77
in general payments reported to CMS, 2019-2025
29 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $415 · 2023: $1,301 · 2024: $1,671 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,200 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,199.64 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $846.04 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $759.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $725.52 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $698.12 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $398.35 | 2022-2025 | Spravato |
| Amgen INC. | $355.49 | 2023-2025 | Repatha, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $339.12 | 2022-2025 | |
| Abbvie INC. | $337.34 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $220.85 | 2021-2025 | Verquvo, Lagevrio, Capvaxive |
| Exact Sciences Corporation | $184.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $163.91 | 2021-2025 | |
| Astellas Pharma US INC | $103.43 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.21 | 2021-2025 | Jardiance |
| Dexcom, INC. | $67.76 | 2023-2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $61.84 | 2023 | Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $50.68 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $49.67 | 2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.82 | 2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $43.12 | 2023 | Austedo, Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $42.75 | 2021-2024 | Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.61 | 2023-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $38.72 | 2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $36.36 | 2025 | |
| Idorsia Pharmaceuticals US INC | $33.79 | 2022 | |
| Phathom Pharmaceuticals, INC. | $29.69 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $26.95 | 2025 | |
| Horizon Therapeutics Plc | $25.69 | 2022 | |
| Amarin Pharma, INC. | $20.52 | 2021 | |
| Averitas Pharma INC. | $19.63 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.